Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

LIN vs AIQUY: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

LIN Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)

LIN Overall Winner 6-Pillar Tally: LIN 6 – 0 AIQUY Matrix Metrics: LIN 9 – 1 AIQUY

As of Nov 16, 2026, Linde plc Ordinary Share (LIN) is the stronger overall head-to-head candidate over AIQUY (AIQUY) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LIN carries a Unified Composite Score of 39.3/100 (SELL) at $526.29 (28.9x Forward P/E, 27.6% operating margin), whereas AIQUY carries 36.5/100 (SELL) at $42.56 (N/M Forward P/E, N/A operating margin).

  • Defensive Composite Rating Caution: Although LIN compares more favorably head-to-head, both LIN (39.3/100 SELL) and AIQUY (36.5/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LIN vs AIQUY
LIN NASDAQ Head-to-Head Winner
Linde plc Ordinary Share
Industrial Inorganic Chemicals
$526.29
+0.04% 1D
Market Cap $239.9B
TTM Revenue $36.2B
Forward P/E 28.9x
Beta / 30D Vol 0.01β · 17% Vol
Unified Composite Score
39.3 / 100 SELL
Tech 32.0 Fund 36.0 Flow 52.0 Mom 21.4
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.5% over 20 days), RSI 66
RSI-14: 66.1 · SMA20: $515.09 · SMA50: $491.22
AIQUY US Equity
AIQUY
Institutional Equity
$42.56
+0.02% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.32β · 18% Vol
Unified Composite Score
36.5 / 100 SELL
Tech 5.0 Fund 30.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.4% over 20 days), RSI 73
RSI-14: 73.0 · SMA20: $40.60 · SMA50: $39.21

6-Pillar Scorecard Institutional Category Breakdown (LIN 6 – 0 AIQUY)

Columns: Metric · LIN · AIQUY
1. Valuation Multiples LIN
Forward P/E 28.9x N/M
Trailing P/E 34.7x N/M
PEG Ratio 2.07x N/M
EV / Revenue 7.2x N/M
2. Growth & Scale LIN
Revenue Growth (YoY) +9.2% N/A
Earnings Growth (YoY) -10.5% N/A
TTM Revenue (USD) $36.2B N/A
Market Cap $239.9B N/A
3. Profitability & Quality LIN
Gross Margin 47.9% N/A
Operating Margin 27.6% N/A
Net Profit Margin 19.3% N/A
Return on Equity (ROE) 17.7% N/A
4. Balance Sheet & Cash Flow LIN
Cash Generation (TTM) $5.08B N/A
Cash Flow Margin 14.0% N/A
Net Cash / Leverage $22.8B Net Debt (0.68x D/E) N/A ROE
Dividend Yield 1.20% None (0.00%)
5. Options & Positioning LIN
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 20.5% (45th %ile) N/A (N/A)
Put/Call OI Skew 1.60x (Put-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat LIN
OpEx & R&D Intensity 20.3% of Rev ($7.36B) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Specialty Chemicals Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LIN (9) vs AIQUY (1)
Institutional Metric LIN AIQUY Criterion Row Edge
Market Capitalization
Scale
$239.9B N/A Larger Scale LIN
Trailing P/E Ratio
Valuation
34.7x N/M Lower Multiple LIN
Forward P/E Ratio
Valuation
28.9x N/M Lower Multiple LIN
Revenue Growth (YoY)
Growth
+9.2% N/A Higher Growth LIN
Operating Margin (TTM)
Profitability
27.6% N/A Higher Margin LIN
Net Profit Margin
Profitability
19.3% N/A Higher Margin LIN
Return on Equity (ROE)
Capital Efficiency
17.7% N/A Higher ROE LIN
52-Week Range Position
Momentum
86% ($388–$548) 96% ($33–$43) Stronger Trend AIQUY
Beta / 30D Volatility
Risk Regime
0.01β · 17% Vol 0.32β · 18% Vol Lower Realized Risk LIN
Unified Institutional Score
Composite Signal
39.3 / 100 (SELL) 36.5 / 100 (SELL) Higher Composite LIN
Trailing 12M Revenue (USD)
Operating Scale
$36.2B N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
47.9% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.07x PEG · 7.2x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$5.08B ($22.8B Net Debt (0.68x D/E)) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AIQUY +3.12 pp
LIN: +6.66% · AIQUY: +9.78%
3M Horizon LIN +0.65 pp
LIN: +10.91% · AIQUY: +10.26%
6M Horizon AIQUY +13.04 pp
LIN: +3.94% · AIQUY: +16.98%
1Y Horizon LIN +6.24 pp
LIN: +22.73% · AIQUY: +16.49%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LIN vs AIQUY. Trailing 12-month operating profitability (LIN 27.6% vs AIQUY N/A) and valuation multiples (LIN 28.9x vs AIQUY N/M Forward P/E) are benchmarked directly in Pillar 4 below.

LIN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$36.2B
Gross Margin47.9%
Op. Margin27.6%
ROE / Fwd P/E17.7% · 28.9x
AIQUY ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LIN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 20.5%
IV Percentile 45th %ile
Put/Call OI Skew 1.60x (Put-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact LIN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AIQUY UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AIQUY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LIN Moat Profile Scale & Operating Efficiency Moat
Specialty Chemicals Operator
Competes within the Specialty Chemicals value chain with $239.9B market capitalization and 27.6% operating margin.
OpEx & R&D Reinvestment 20.3% of Rev ($7.36B)
90D Engineering Disclosures 0 Published
Mapped Supply-Chain Ecosystem (15 partners):
Exxon Mobil Corporation Chevron Corporation BASF SE Dow Inc.
AIQUY Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ LIN vs AIQUY Key Questions & Quantitative Answers

As of Nov 16, 2026, Linde plc Ordinary Share (LIN) is the stronger overall head-to-head candidate over AIQUY (AIQUY) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LIN carries a Unified Composite Score of 39.3/100 (SELL) at $526.29 (28.9x Forward P/E, 27.6% operating margin), whereas AIQUY carries 36.5/100 (SELL) at $42.56 (N/M Forward P/E, N/A operating margin). Defensive Composite Rating Caution: Although LIN compares more favorably head-to-head, both LIN (39.3/100 SELL) and AIQUY (36.5/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

LIN leads the Growth & Scale pillar: LIN posts +9.2% YoY revenue growth and -10.5% YoY earnings growth on $36.2B TTM revenue (47.9% gross margin, 27.6% operating margin), compared with AIQUY at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, LIN generates $36.2B in USD-normalized revenue versus N/A for AIQUY. In operating R&D and SG&A reinvestment, LIN deploys 20.3% of Rev ($7.36B) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AIQUY.

LIN screens cheaper on headline valuation multiples. LIN trades at 28.9x Forward P/E, 34.7x Trailing P/E, 2.07x PEG, and 7.2x EV/Revenue (14.0% FCF margin), whereas AIQUY trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LIN (17.7% ROE) versus AIQUY (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, LIN carries 20.5% implied volatility (45th %ile, Balanced (25th–60th %ile)), a 1.60x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.01β · 17% Vol realized risk). By comparison, AIQUY carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.32β · 18% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.